# Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response

Study · id `cardio:ct-nct05691959` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05691959](<https://clinicaltrials.gov/study/NCT05691959>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05691959

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 378 participants.

## Technical summary

Registry record NCT05691959. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-26 (anticipated); primary completion 2025-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 378 participants (planned count; ClinicalTrials.gov record NCT05691959, source copy `cardio:ctgov-nct05691959-2023-01-20`, retrieved 2026-10-26)
- Planned start: 2023-01-26 (anticipated) (ClinicalTrials.gov record NCT05691959, source copy `cardio:ctgov-nct05691959-2023-01-20`, retrieved 2026-10-26)
- Primary completion: 2025-01-31 (anticipated) (ClinicalTrials.gov record NCT05691959, source copy `cardio:ctgov-nct05691959-2023-01-20`, retrieved 2026-10-26)
- Completion: 2025-01-31 (anticipated) (ClinicalTrials.gov record NCT05691959, source copy `cardio:ctgov-nct05691959-2023-01-20`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05691959-2023-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response
- Condition: Atrial Fibrillation With Rapid Ventricular Response
- Condition: Hypotension
- Intervention (Drug): Placebo
- Intervention (Drug): Calcium
- Lead sponsor: Ascension Health
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 1e9e57923217447243e112c58e8e316dc299fd4611b66d02c176ba266eacf77d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
